cGMP XRPD Services

XRPD is usually the appropriate starting technique when the primary question concerns crystalline phase identity, polymorphism, crystallinity, amorphous content, hydrate or solvate formation, or a solid-state transformation. It provides a rapid and largely nondestructive fingerprint of long-range crystalline order. XRPD should generally be combined with other methods when the question also involves chemical identity, water or solvent content, proton transfer, molecular structure, thermal behavior, or low-level phase quantitation.

Yes. XRPD is generally the primary analytical technique for distinguishing pharmaceutical polymorphs because each polymorph has a different crystal structure and normally produces a distinct set of diffraction peaks. Reliable identification depends on representative reference patterns, suitable data quality, controlled sample preparation, and consideration of mixtures, preferred orientation, peak overlap, crystallite size, and hydration or solvation. XRPD may require complementary methods when forms are poorly crystalline, structurally similar, present at low concentration, or transformed during analysis.

Routine XRPD commonly uses tens to hundreds of milligrams of powder, but the actual requirement depends on instrument geometry, holder design, sample density, absorption, particle statistics, and the analytical objective. Useful data can often be collected from a few milligrams using low-volume or zero-background holders, and specialized transmission or capillary methods may require even less. Smaller samples generally produce weaker signals and greater sensitivity to preparation, orientation, heterogeneity, and particle statistics.

XRPD quality is affected by sample crystallinity, crystallite size, particle size, preferred orientation, phase concentration, absorption, sample thickness, packing, displacement, surface flatness, instrument alignment, optics, scan conditions, background, environmental exposure, and data processing. Poor-quality patterns do not necessarily indicate poor-quality material; they may reflect preparation or measurement artifacts. Reliable interpretation requires distinguishing true solid-state characteristics from instrumental and specimen-related effects.

Quantitative XRPD is appropriate when the amount of one or more crystalline phases must be measured rather than merely identified and when differences in phase concentration affect product quality, performance, stability, manufacturing control, or regulatory compliance. Suitable applications include polymorph mixtures, residual crystalline API, hydrate or solvate content, phase conversion, crystalline contaminants, and total amorphous content. Reliable quantitation requires representative standards or validated structural models, controlled sample preparation, adequate specificity, and demonstrated accuracy, precision, range, robustness, and detection capability.

XRPD is highly effective for evaluating long-range crystalline order, but it does not independently establish chemical identity, molecular connectivity, protonation state, water or solvent content, purity, thermodynamic stability, or product performance. Its sensitivity may be limited for low-level phases, amorphous material, nanocrystals, poorly crystalline samples, complex formulations, and phases with overlapping patterns. Results are also influenced by sample preparation, preferred orientation, particle statistics, absorption, background, and environmental transformation. XRPD is therefore strongest when used as part of an orthogonal analytical strategy.

XRPD and thermal analysis should be used as complementary techniques because they measure different attributes of a pharmaceutical solid. XRPD identifies crystalline phases and changes in long-range order, while DSC evaluates heat-flow events such as melting, glass transition, crystallization, and solid–solid transitions, and TGA measures mass changes associated with water, solvent, decomposition, or volatilization. Correlating the techniques helps distinguish polymorphic transitions, melting, desolvation, dehydration, recrystallization, and decomposition more reliably than any one method alone.

XRPD results in formulation development should be interpreted in relation to the formulation objective, API concentration, excipient matrix, processing history, analytical capability, and product-performance data. The presence, absence, or change of diffraction peaks may indicate polymorphic conversion, recrystallization, hydration, desolvation, salt disproportionation, cocrystal dissociation, or processing-induced disorder, but peak changes can also result from dilution, overlap, preferred orientation, particle size, or sample preparation. XRPD findings should therefore be correlated with thermal analysis, spectroscopy, moisture studies, chemical analysis, dissolution, and manufacturing conditions.